K J Savage

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    Kerry J Savage
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3871-9. 2003
  2. ncbi request reprint Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
    K J Savage
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Ann Oncol 15:1467-75. 2004
  3. ncbi request reprint Peripheral T-cell lymphomas
    Kerry J Savage
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada
    Blood Rev 21:201-16. 2007
  4. doi request reprint Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors
    Vivien Mak
    Princess Margaret Hospital, Hong Kong, China
    J Clin Oncol 31:1970-6. 2013
  5. doi request reprint Therapies for peripheral T-cell lymphomas
    Kerry J Savage
    BC Cancer Agency, Vancouver, BC
    Hematology Am Soc Hematol Educ Program 2011:515-24. 2011
  6. doi request reprint Update: peripheral T-cell lymphomas
    Kerry J Savage
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Curr Hematol Malig Rep 6:222-30. 2011
  7. doi request reprint Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
    Kerry J Savage
    Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
    Blood 118:4585-90. 2011
  8. doi request reprint MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z4E6
    Blood 114:3533-7. 2009
  9. doi request reprint ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
  10. ncbi request reprint Primary mediastinal large B-cell lymphoma
    Kerry J Savage
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada
    Oncologist 11:488-95. 2006

Collaborators

Detail Information

Publications36

  1. ncbi request reprint The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    Kerry J Savage
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3871-9. 2003
    ..In almost all cases, c-REL was localized to the nucleus, consistent with activation of the NF-kappa B pathway. These studies identify a molecular link between MLBCL and cHL and a shared survival pathway...
  2. ncbi request reprint Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
    K J Savage
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Ann Oncol 15:1467-75. 2004
    ....
  3. ncbi request reprint Peripheral T-cell lymphomas
    Kerry J Savage
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada
    Blood Rev 21:201-16. 2007
    ..Future clinical trials are needed that focus specifically on PTCL to advance our understanding and define the optimal management in this disease...
  4. doi request reprint Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors
    Vivien Mak
    Princess Margaret Hospital, Hong Kong, China
    J Clin Oncol 31:1970-6. 2013
    ....
  5. doi request reprint Therapies for peripheral T-cell lymphomas
    Kerry J Savage
    BC Cancer Agency, Vancouver, BC
    Hematology Am Soc Hematol Educ Program 2011:515-24. 2011
    ....
  6. doi request reprint Update: peripheral T-cell lymphomas
    Kerry J Savage
    British Columbia Cancer Agency, Vancouver, BC, Canada
    Curr Hematol Malig Rep 6:222-30. 2011
    ..The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs...
  7. doi request reprint Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
    Kerry J Savage
    Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
    Blood 118:4585-90. 2011
    ..0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone...
  8. doi request reprint MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z4E6
    Blood 114:3533-7. 2009
    ..In the R-CHOP treatment era, MYC+ DLBCLs have an inferior prognosis. Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested...
  9. doi request reprint ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
    ..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...
  10. ncbi request reprint Primary mediastinal large B-cell lymphoma
    Kerry J Savage
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada
    Oncologist 11:488-95. 2006
    ..Clinical trials exploring these questions in addition to the benefit of consolidative radiotherapy are necessary to definitively answer these questions...
  11. ncbi request reprint Molecular signatures of lymphoma
    Kerry J Savage
    Division of aMedical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Int J Hematol 80:401-9. 2004
    ..In this review, we have endeavored to include data from multiple investigator groups and tried to cover the breadth of lymphoid tumors, excluding acute and chronic leukemias...
  12. ncbi request reprint Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
    K J Savage
    University of British Columbia and the British Columbia Cancer Agency, Vancouver, BC, Canada
    Ann Oncol 17:123-30. 2006
    ..The optimal treatment is unknown, with some studies suggesting a superior outcome with dose-intensive chemotherapy regimens, and the role of radiotherapy remains ill-defined...
  13. doi request reprint Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
    D Villa
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Ann Oncol 21:1046-52. 2010
    ..We evaluated the risk of central nervous system (CNS) relapse in the R-CHOP in a population-based cohort of patients with DLBCL...
  14. pmc Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
    Nathalie A Johnson
    Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 114:2273-9. 2009
    ..A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL2-targeted therapy...
  15. doi request reprint Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma
    Mubarak Al-Mansour
    MSc, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, British Columbia, V5Z 4E6
    J Clin Oncol 28:793-9. 2010
    ..Because transformation can occur years after the primary diagnosis of NLPHL, long-term follow-up of these individuals is necessary to accurately estimate the risk of development of secondary DLBCL...
  16. doi request reprint Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size
    Belinda A Campbell
    Department of Radiation Oncology, Pathology, and Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    J Clin Oncol 26:5170-4. 2008
    ..Recent publications recommend a further reduction to involved-nodal radiation therapy (INRT), however, this has not been clinically validated...
  17. doi request reprint Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    Abdulwahab J Al-Tourah
    Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    J Clin Oncol 26:5165-9. 2008
    ..To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)...
  18. ncbi request reprint A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial
    Christopher W Lee
    BC Cancer Agency Fraser Valley Centre, 13750 96th Avenue, Surrey, BC, Canada V3V 1Z2
    Invest New Drugs 26:249-55. 2008
    ..Although KSP expression appears to be common in melanoma, KSP may not be a suitable target for its treatment...
  19. ncbi request reprint The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  20. ncbi request reprint Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis
    Janessa J Laskin
    Division of Medical Oncology, University of British Columbia and the British Columbia Cancer Agency, Vancouver, BC, Canada
    Leuk Lymphoma 46:1721-7. 2005
    ..Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse...
  21. doi request reprint Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy
    P Bains
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada
    Ann Oncol 24:428-32. 2013
    ..There is an inherent risk of transformation of follicular lymphoma to aggressive lymphoma; however, the frequency and impact on the outcome are unknown in limited-stage patients...
  22. pmc Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide
    Christina Kim
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    Oncologist 15:765-71. 2010
    ..Patients with metastatic melanoma typically have a poor outcome; however, a small proportion of patients achieve long-term survival (LTS). It is unclear how often LTS is related to sensitivity to chemotherapy...
  23. doi request reprint Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy
    Belinda A Campbell
    Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 116:3797-806. 2010
    ....
  24. doi request reprint Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission
    A Bestawros
    Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada
    Ann Oncol 24:1359-63. 2013
    ..Guidelines are based on consensus rather than high-quality evidence. It is unknown if routine screening leads to earlier relapse detection or translates into better outcomes...
  25. doi request reprint The spectrum of peripheral T-cell lymphomas
    Hilary O'Leary
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Curr Opin Hematol 16:292-8. 2009
    ....
  26. ncbi request reprint Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient
    Joanna K Law
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Hematol 81:969-72. 2006
    ..Our experience indicates the need to carefully monitor patients for suspected drug- resistant HBV mutants with the addition of anti-viral agents effective against the YMDD mutational strain, when lamivudine resistance emerges...
  27. ncbi request reprint Frequent occurrence of deletions in primary mediastinal B-cell lymphoma
    Lindsey R Kimm
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Genes Chromosomes Cancer 46:1090-7. 2007
    ..We conclude that consistent losses are present in the PMBCL genome. Given the similar frequency of losses to that of segmental gains of DNA, they are likely to play an important role in the pathogenesis of PMBCL...
  28. ncbi request reprint Novel therapies in peripheral T-cell lymphomas
    Hilary M O'Leary
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada
    Curr Oncol Rep 10:404-11. 2008
    ..The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in PTCLs...
  29. doi request reprint Update on the World Health Organization classification of peripheral T-cell lymphomas
    Hilary M O'Leary
    British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
    Curr Hematol Malig Rep 4:227-35. 2009
    ..This review summarizes the changes in the fourth edition of the WHO classification of lymphoid tumors, with particular focus on the aggressive subtypes...
  30. ncbi request reprint Rare B-cell lymphomas: primary mediastinal, intravascular, and primary effusion lymphoma
    Kerry J Savage
    British Columbia Cancer Agency, Vancouver, Canada
    Cancer Treat Res 142:243-64. 2008
  31. ncbi request reprint NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
    Friedrich Feuerhake
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1392-9. 2005
    ..In this large series of primary MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms...
  32. ncbi request reprint TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Surg Pathol 29:196-203. 2005
    ....
  33. ncbi request reprint Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Surg Pathol 31:106-12. 2007
    ..Thus, the combined nuclear localization of c-Rel and the cellular expression of TRAF1 is a highly specific (specificity=98%) means to distinguish PMLBCL from DLBCL that is readily applicable to routine surgical pathology practice...
  34. ncbi request reprint Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
    Michael J Robertson
    Indiana University Medical Center, Indianapolis, IN, USA
    J Clin Oncol 25:1741-6. 2007
    ..We conducted a multicenter phase II study of a potent inhibitor of PKCbeta, enzastaurin, in patients with relapsed or refractory DLBCL...
  35. ncbi request reprint Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...
  36. doi request reprint Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma
    Marilu Nelson
    Human Genetics Laboratories, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE 68198 5440, USA
    Br J Haematol 141:461-9. 2008
    ..Although, genetic differences were noted in these subtypes, further studies are needed to determine the key pathogenetic events in PTCL...